BioPharma Credit (LON:BPCR - Get Free Report) traded down 0.7% on Wednesday . The stock traded as low as GBX 0.85 ($0.01) and last traded at GBX 0.85 ($0.01). 183,907 shares were traded during mid-day trading, a decline of 80% from the average session volume of 928,503 shares. The stock had previously closed at GBX 0.86 ($0.01).
BioPharma Credit Stock Performance
The stock has a market capitalization of £1.03 billion, a P/E ratio of 9.87 and a beta of 0.22. The firm's fifty day simple moving average is GBX 0.87 and its 200 day simple moving average is GBX 0.86.
BioPharma Credit Cuts Dividend
The company also recently disclosed a dividend, which will be paid on Wednesday, May 7th. Investors of record on Thursday, April 3rd will be issued a dividend of $0.02 per share. This represents a dividend yield of 1.99%. The ex-dividend date is Thursday, April 3rd. BioPharma Credit's dividend payout ratio (DPR) is 7,957.15%.
BioPharma Credit Company Profile
(
Get Free Report)
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom.
Read More
Before you consider BioPharma Credit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioPharma Credit wasn't on the list.
While BioPharma Credit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.